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Background/Aims:  The optimal timing for interventional 
endoscopy in bleeding peptic ulcer disease is con-
troversial. This study compared the outcomes between 
early endoscopy and delayed endoscopy in patients 
with bleeding peptic ulcer disease. Methods:  We con-
ducted a prospective analysis of data from 90 patients 
with bleeding peptic ulcer disease who visited the 
emergency room between May 2006 and September 
2007. Patients were categorized into two groups: the 
early-endoscopy group (admitted during the daytime or 
at night with prompt endoscopic management) and the 
delayed-endoscopy group (admitted at night or during 
weekends, with endoscopic management delayed until 
the next day). We compared the clinical outcomes of 
endoscopy between the two groups. Results:  There 
were 49 patients in the early-endoscopy group and 41 
patients in the delayed-endoscopy group. Patient dem-
ographics, clinical characteristics, bleeding control mo-
dality, and Rockall score did not differ between the 
two groups. There were also no significant differences 
between the early- and delayed-endoscopy groups in 
the re-bleeding rate (3/49 vs 5/41, p=0.313), the dura-
tion of hospital stay (10.7 vs 9.3 days, p=0.437), and 
the total amount of blood transfused (3.4 vs 2.7 units, 
p=0.240).  Conclusions: The effectiveness of interven-
tional endoscopy for patients with bleeding peptic ul-
cer disease is not significantly affected by the timing 
of endoscopy. (Gut and Liver 2009;3:266-270)
Key Words: Bleeding peptic ulcer disease; Interven-
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INTRODUCTION
  Acute upper gastrointestinal hemorrhage (UGIH) is a 
common emergency in most hospitals.
1 Peptic ulcer dis-
e a s e  i s  t h e  m o s t  c o m m o n  e t i o l o g y  o f  U G I H ,  a n d  m o r e  
than 40% of acute UGIH cases in North America may be 
attributed to bleeding peptic ulcers.
2 Despite considerable 
advances in endoscopic hemostatic modalities and phar-
macologic treatment, bleeding peptic ulcers still cause sig-
nificant morbidity and mortality, usually due to advanced 
patient age and prevalence of concomitant diseases.
3 Mor-
tality remains around 12% and may be as high as 20% 
among elderly patients and those with substantial 
co-morbidities.
1,4 Hemorrhage occurs in 20-30% of pa-
tients with peptic ulcer disease. In 70-80% of UGIH cas-
es, bleeding is controlled with conservative management, 
but endoscopic therapy is beneficial in patients with pep-
tic ulcer disease and active bleeding demonstrating visible 
vessels.
5,6 Currently, endoscopy has been established as 
an effective treatment for acute UGIH, especially bleeding 
peptic ulcers, and is the standard of care for patients with 
this condition.
5,6
    The optimal timing of interventional endoscopy for 
bleeding peptic ulcer disease is controversial. In pro-
spective studies, early endoscopy was shown to provide 
clinical benefit by promoting safe patient predisposi-
tion.
7,8 In retrospective studies, early endoscopy also re-
sulted in significant reductions in length of stay and the 
rate of recurrent bleeding or surgery for high- and 
low-risk groups.
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endoscopy performed less than 8 hours after admission 
showed no definite benefit in comparison with urgent en-
doscopy performed within eight to 24 hours in high-risk 
UGIH patients.
10
  In the daytime, early endoscopic treatment is readily 
available and safe. However, it is especially difficult to 
manage incidental problems that might arise at nighttime 
or during weekends due to lack of sufficient medical per-
sonnel, medical facilities, and surgical back-up. In addi-
tion, various complications, such as hemorrhage, perfora-
tion, and aspiration may result from early endoscopic 
treatment.
11 The aim of this study was to compare the 
clinical outcomes between early endoscopy and delayed 
endoscopy in patients with bleeding peptic ulcer disease.
MATERIALS AND METHODS
  We conducted a prospective analysis of data from 125 
patients with UGIH who visited the emergency room with 
a suspected bleeding peptic ulcer from May 2006 to 
September 2007 (age range, 18-80 years). All patients 
demonstrated UGIH symptoms such as hematemesis, me-
lena, or hematochezia, with coffee-ground or bloody naso-
gastric aspirate. We enrolled the patients who were diag-
nosed with peptic ulcer(s) on endoscopy. Exclusion cri-
teria were as follows: (i) cancer bleeding (n=6), (ii) varix 
bleeding (n=8), (iii) Mallory-Weiss syndrome (n=8), (iv) 
angiodysplasia (n=2), (v) acute gastric mucosal lesion 
(AGML) (n=1), and (vi) transference to a different medi-
cal facility (n=10). As a consequence, 90 patients were 
enrolled in our study. 
  In most studies, the definition of early endoscopy is de-
termined by time to endoscopy after admission. But in 
our study, the definition of early endoscopy was de-
termined more practically. Patients were categorized into 
two groups. The early endoscopy group included patients 
admitted during the daytime or even at night, with 
prompt endoscopic management. The other group was the 
delayed endoscopy group patients, who were admitted at 
night or during the weekends, with delayed endoscopic 
management until the next day.
  We investigated and assessed the following clinical pa-
rameters: age, clinical symptoms (hematemesis, melena, 
hematochezia), comorbidity, medication history (NSAIDs, 
anti-platelet drugs), history of peptic ulcer or bleeding, 
and clinical signs and laboratory findings at admission 
(shock status, initial hemoglobin, etc). We also calculated 
the Rockall score for all patients.
12 Pre-endoscopic scores 
were made up of three risk factors (age, shock, and co-
morbidity) and post-endoscopic scores were consisted of 
endoscopic findings and stigmata of bleeding. Total Roc-
kall scores were calculated as the sum of pre-endoscopic 
scores and post-endoscopic scores (total score range, 
0-10). 
  Endoscopic procedures were performed by three gastro-
enterologists consisted of two fellows and one faculty. 
There was no difference in endoscopist’s experiences in 
performing endoscopic therapy between two groups.
  In the delayed endoscopy group, we treated with an 80 
mg bolus of intravernous pantoprazole followed by con-
tinuous infusion of intravenous pantoprazole 8 mg per 
hour for 72 hours before and after endoscopy. Early en-
d o s c o p y  g r o u p  w e r e  t r e a t e d  w i t h  a n  8 0  m g  b o l u s  o f  i n -
tavernous pantoprazole before endoscopy, and continuous 
i n f u s i o n  o f  i n t r a v e n o u s  p a n t o p r a z o l e  8  m g  p e r  h o u r  f o r  
72 hours after endoscopy.
  Endoscopic findings noted were bleeding site, the size 
of ulcer, and the stages of ulceration using the Forrest 
classification. Endoscopic therapy was performed in all 
patients with Forrest type Ia to IIa ulcers and in some pa-
tients with Forrest type IIb or III ulcers. Therapeutic mo-
dalities included epinephrine injection, alcohol injection, 
hemoclip placement, and argon plasma coagulation 
(APC). According to the amount of bleeding, the extent 
of ulceration, and the degree of vessel exposure, we used 
single or combined interventional therapy. Re-bleeding 
was defined as fresh hematemesis, melena, or hema-
tochezia, and reduction in hemoblobin level in excess of 2 
g/dL between 6 hours and 2 weeks after clinical stability. 
  We compared clinical outcomes, such as the rate of 
re-bleeding, duration of hospital stay, and the total 
amount of transfusion between the two groups. This stu-
dy was carried out in accordance with the Helsinki decla-
r a t i o n  a s  r e v i s e d  i n  1 9 8 9  a n d  a p p r o v e d  b y  i n s t i t u t i o n a l  
review board in Hanyang University Guri Hospital.
Statistical analysis
  We analyzed demographic characteristics, clinical char-
acteristics, endoscopic findings, therapeutic modalities, 
and clinical outcomes by categorization of the early and 
delayed endoscopy groups. Categorical data were com-
pared using Fisher’s exact test or a chi-squared test, and 
comparisons of continuous data were made using the 
Mann-Whitney test. p values of less than 0.05 were con-
sidered to be statistically significant. All analyses were 
performed using SPSS 12.0 version (SPSS Inc., Chicago, 
IL, USA).
RESULTS
  A total of 90 patients with peptic ulcer bleeding were 
enrolled. Of these, 49 underwent early endoscopy (37 268   Gut and Liver, Vol. 3, No. 4, December 2009
Table 2. Clinical Characteristics of the Study Patients
Early, No. (%)
(n=49)
Delayed, No. (%)
(n=41)
Total, No. (%)
(n=90)
p-value
Hematemesis 
Melena 
Hematochezia 
Shock (sys<100 mm Hg)
Heart rate (beats/min)
Hemoglobin
27 (55.1)
41 (83.7)
 6 (12.2)
13 (26.5)
90.78±19.13
8.74±2.44
22 (53.7)
31 (75.6)
 5 (12.2)
 6 (14.6)
90.88±16.61
9.58±2.03
49 (54.4)
72 (80.0)
11 (12.2)
19 (21.1)
90.82±17.93
9.12±2.30
0.891
0.341
0.994
0.168
0.978
0.082
Plus-minus values are means±SD.
Table 1. Demographic Characteristics of the Study Patients
Early, 
No. (%)
(n=49)
Delayed, 
No. (%)
(n=41)
Total, 
No. (%) 
(n=90)
p-value
Age (years)
Sex (M:F)
Comorbidity (%)
  I H D  ( % )
  H T N  ( % )
  D M  ( % )
  R e n a l  ( % )
  H e p a t i c  ( % )
  P u l m o n a r y  ( % )
  O t h e r s  ( % )
Medication (%)
Ulcer history (%)
Bleeding history (%)
58.7±15.9
37:12
 26 (53.1)
  2  ( 4 . 1 )
 15 (30.6)
  8 (16.3)
  2  ( 4 . 1 )
  5 (10.2)
  2  ( 4 . 1 )
  4  ( 8 . 2 )
 17 (34.7)
  7 (14.3)
  4  ( 8 . 2 )
55.9±14.8
34:7
 22 (53.7)
  3  ( 7 . 3 )
 11 (26.8)
  9 (22.0)
  1  ( 2 . 4 )
  6 (14.6)
  1  ( 2 . 4 )
  3  ( 7 . 3 )
 17 (41.5)
 11 (26.8)
  7 (17.1)
57.4±15.4
71:19
 48 (53.3)
  5  ( 5 . 5 )
 26 (28.8)
 17 (18.8)
  3  ( 3 . 3 )
 11 (12.2)
  3  ( 3 . 3 )
  7  ( 7 . 7 )
 34 (37.7)
 18 (20.0)
 11 (12.2)
 0.396
 0.391
 0.955
 0.505
 0.693
 0.497
 0.665
 0.523
 0.665
 0.881
 0.509
 0.138
 0.199
Plus-minus values are means±SD.
IHD, ischemic heart disease; HTN, hypertension; DM, diabetes 
mellitus.
Table 4. Clinical Outcomes according to the Timing of En-
doscopy
Early, 
No. (%)
(n=49)
Delayed, 
No. (%)
(n=41)
Total, 
No. (%)
(n=90)
p-value
Transfusion 
 requirement (u)
Hospital day
Recurrent
 bleeding
3.41±2.79
10.69±10.62
3 (6.1)
2.73±2.62
9.34±5.33
5 (12.2)
 3.10±2.72
10.08±8.61
8 (8.9)
0.240
0.437
0.313
Plus-minus values are means±SD.
u, unit.
Table 3. Endoscopic Findings and Treatment Modalities
Early, 
No. (%)
(n=49)
Delayed, 
No. (%)
(n=41)
Total, 
No. (%)
(n=90)
p-value
Gastric ulcer
Duodenal ulcer
Both
Forrest type 
    I a 
    I b 
    I I a 
    I I b 
    I I c 
    I I I
Control method
  Single modality
  Combined therapy
32 (65.3)
12 (24.5)
 5 (10.2)
 2 (4.1)
 4 (8.2)
16 (32.7)
20 (40.8)
 3 (6.1)
 4 (8.2)
38 (77.6)
24 (49.0)
14 (28.6)
28 (68.3)
12 (29.3)
 1 (2.4)
 2 (4.9)
 4 (9.8)
10 (24.4)
13 (31.7)
 7 (17.1)
 5 (12.2)
33 (80.5)
21 (51.2)
12 (29.3)
60 (66.6)
24 (26.6)
 6 (6.6)
 4 (4.4)
 8 (8.9)
26 (28.8)
33 (36.6)
10 (11.1)
 9 (10.0)
71 (78.8)
45 (50.0)
26 (28.8)
0.765
0.610
0.141
0.855
0.791  
0.389
0.372
0.100
0.525
0.734
0.832
0.942
men; mean age, 58.7 years) and 41 underwent delayed 
endoscopy (34 men; mean age, 55.9 years). The difference 
between the groups with respect to these demographic 
characteristics was not statistically significant (Table 1). 
Clinical characteristics of the patients are shown in Table 
2. Major presentations including hematemesis, melena, 
hematochezia, systolic blood pressure, heart rate, and he-
moglobin also showed no statistically significant differ-
ence between groups. The mean duration from admission 
to initial endoscopic examination was 18.63 hours in the 
delayed endoscopy group, and 4.02 hours in the early en-
doscopy group. Endoscopic findings are shown in Table 3. 
Gastric ulcers were more common than duodenal ulcers 
(66.6%, 26.6%, respectively), but their frequencies did 
not differ between the two groups. In staging of ulcers by 
Forrest classification, there was no statistically significant 
difference between the two groups. Endoscopic treatment 
was performed in 71 patients (78.8%). All patients with 
active bleeding (Forrest type Ia and Ib) and with visible 
vessels (Forrest type IIa) received endoscopic treatment. 
In Forrest type IIb, adherent clots were removed and en-
doscopic treatment of the underlying lesion was per-
formed, but if clots were too small and showed no evi-
dence of bleeding, the treatment was not performed. 
Thirty-eight patients (77.6%) in the early endoscopy 
group and 33 patients (80.5%) in the delayed endoscopy 
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dality showed no significant difference in either group. 
Clinical outcomes are shown in Table 4. The total Rockall 
score was not statistically different between the two 
groups (5.1±1.9 vs 4.9±1.5, p=0.08). The total amount 
of blood transfused and hospital days were similar in 
both groups. Furthermore, there was no significant differ-
ence in recurrent bleeding rate between the early endos-
copy group and delayed endoscopy group (6.1% vs 12.2%, 
p=0.313). 
DISCUSSION 
    The optimal timing of interventional endoscopy for 
bleeding peptic ulcer disease has not been clearly estab-
lished, and no consensus exists regarding the benefits and 
costs of early endoscopy in UGIH. Previous studies have 
shown that intensive resuscitation and prompt, aggressive 
endoscopic therapy reduces mortality in acute nonvariceal 
UGIH.
6 According to a systematic review, the existing da-
ta suggests that early endoscopy might be safe and effec-
tive for all risk groups.
13 On the other hand, Schacher et 
al. showed that early endoscopy in an emergency room 
did not improve the clinical outcome in patients with 
bleeding peptic ulcers.
14 Furthermore, in a recent study, 
emergency endoscopy performed less than 8 hours after 
admission showed no definite benefit in comparison to 
urgent endoscopy performed within 8 to 24 hours in 
high-risk UGIH patients.
10 In the current study, the clin-
ical outcomes including transfusion rate, length of hospi-
talization, and re-bleeding rate did not differ between the 
early and delayed endoscopy group patients.
  There is no general consensus on the definition of early 
endoscopy in UGIH as yet. In previous studies, the defi-
nition of early endoscopy was defined most of the time as 
t h e  in te rv a l f ro m  a d m is s io n  to  e n d o s c o p y , su c h  a s  u n d e r 
8 hours,
10 under 12 hours,
15 and even under 2 hours.
16 
We applied different definitions to the timing of endos-
copy according to when the endoscopy was performed. In 
our study, “early” endoscopy means that it was performed 
“promptly”, regardless of the time it was performed.
  Early endoscopy is difficult to perform in practical sit-
uations, because it not only requires endoscopists, physi-
cians, nurses, and an equipment technician, but it also re-
quires a facility investment and surgical back-up. Some 
studies have shown that early endoscopy might be asso-
ciated with more complications than delayed endoscopy, 
such as significant oxygen desaturation.
16,17 According to 
our results, we suggest that early endoscopy need not be 
unconditionally performed in patients with bleeding pep-
tic ulcers.
  Various endoscopic therapies such as epinephrine in-
jection, hemoclip placement, and argon plasma coagu-
lation (APC) were performed in both groups. No single 
method of endoscopic injection therapy or thermal coap-
tive therapy is superior to another, and it is reasonable to 
use combination modalities to treat high-risk stigmata.
18 
Because the ulcer stage was not significantly different be-
tween the two groups, treatment modality also showed 
no significant difference between the two groups.
  In this study, the clinical outcomes, especially recurrent 
bleeding rate, were not significantly different between the 
early endoscopy group and delayed endoscopy group. The 
recurrent bleeding rate in our study was less than that of 
a previous study (8.9% vs 10%).
10 We reasoned that this 
difference was probably due to the fact that our study in-
cluded all risk groups, whereas the previous study in-
cluded only high-risk patients, and the proportion of ac-
tive bleeding ulcers (Forrest type Ia, Ib) was too small.
  There are several limitations to our study. First, we 
could not carry out out risk stratification according to 
risk factors such as age and vital signs because of the 
small sample size. However, prospective design and data 
of this study are major strengths because previous studies 
for patients with bleeding peptic ulcer are retrospective in 
design.
19,20 It is nevertheless desirable to perform a future 
study that includes more patients and analyzes the results 
by risk stratification. Second, it was difficult to categorize 
the patients into two groups. Although the patients’ dem-
ographic and clinical characteristics showed no significant 
difference between the two groups, a selection bias in the 
definition of early or delayed endoscopy may exist accord-
ing to the clinical situation, medical facilities, and the ex-
perience of the endoscopist. Third, our results are not al-
w a y s  a p p l i c a b l e  i n  a l l  p a t i e n t s  w i t h  U G I H ,  s u c h  a s  v a r i -
ceal bleeding, because we only considered patients with 
peptic ulcer bleeding in this study. Though peptic ulcer 
disease is the most common etiology of UGIH, other eti-
ologies of UGIH cannot be excluded. Hence, we need to 
pay attention to the individual patient’s history, clinical 
features, and origin of bleeding. Last but not the least, 
since the incidence of active bleeding ulcers - especially 
Forrest type Ib - was too small (13.3%), there could be a 
possibility that clinical outcomes between early and de-
layed endoscopy groups have actually no difference.
  Finally, it was not possible to estimate the influence of 
proton-pump inhibitor (PPI) therapy. PPI therapy is war-
ranted in all patients with UGIH severe enough to require 
endoscopic therapy,
21 and combination of endoscopic ther-
apy with PPI is indicated for nonbleeding ulcers at endos-
copy (Forrest type IIa, IIb) with the intent to reduce 
re-bleeding and surgery.
22 PPI therapy is also recom-
mended in patients with suspected peptic ulcer bleeding 270   Gut and Liver, Vol. 3, No. 4, December 2009
associated with hemodynamic instability, and in patients 
for whom endoscopic evaluation is delayed or unavaila-
ble.
21 The re-bleeding rate in the delayed endoscopy 
group was similar to that of early endoscopy group, sug-
gesting the presence of a PPI effect before endoscopy. 
Several trials reported data for re-bleeding within three 
days after PPI treatment. There was a significant differ-
ence in the 3-day re-bleeding rates in favour of PPI treat-
ment compared to control. Especially, high-dose intra-
venous PPI treatment reduced the rates of re-bleeding and 
surgical intervention.
23
  In conclusion, the effectiveness of interventional endos-
copy for patients with bleeding peptic ulcer disease was 
not significantly affected by the timing of endoscopy. In 
other words, early endoscopy performed at night showed 
no definite benefit as compared to delayed endoscopy per-
formed during the day. However, the patient’s history and 
clinical characteristics should be taken into consideration 
when evaluating whether to perform prompt or delayed 
endoscopy according to the clinical situation. Further pro-
spective randomized studies will be needed to demon-
strate the benefits and costs for UGIH patients according 
to the timing of endoscopy.
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